We have previously demonstrated that the oncogenic transcription factor CtBP2 [2], which is frequently overexpressed in pancreatic cancer, as well as colon, breast, ovarian, prostate, and gastric cancers and associated with poor patient outcomes [3–6], is a critical dependency in PDAC, as Ctbp2 allelic loss led to dramatic decreases in tumor size and metastasis along with prolonged survival in PDAC-prone CKP (Pdx1-Cre; LSL-KrasG12D/+; Trp53fl/fl) mice [4]. This evidence concerns the gene CTBP2 and familial pancreatic carcinoma.